前列腺素E1尿激酶在急性脑梗死的临床探讨

A Clinical Study on Protaglandins E1 and Urokinase in the Treatment of the Acute Cerebral Infarction

目的研究探索一种联合用药方法,对急性脑梗死患者进行静脉给药的临床疗效观察。方法将急性脑梗死患者,随机分为两组进行用药观察,联合用药组(46例)和常规单一用药组(37例)进行临床治疗及结论分析。两组年龄,性别,发病及用药时间均无差异。结果联合用药组及常规用药组,两组治疗的临床疗效均达95%,联合组的显著效果明显高于常规组的显著效果。两组结果相比,有显著差异(p<0.05),两组均未发生大量脑出血及严重其它部位出血。结论静脉内联用uk及PGE1对急性脑梗死患者能降低病死率、致残率,可减少并发症的发生率,此治疗方法是一种疗效高、副作用小且安全可靠的治疗方法。

Objective To explore a new thrombolytic therapy to treat the Acute Myocardial infarction by combining Urokinase and Protaglandins El. This new therapy should be high-efficient, practical, inexpensive and convenient with fewer side effects. Method The patients who suffer from the Acute Myocardial Infarction are randomly divided into two groups. There are no differences between the two group in age, sex and their last period of disease and medication. One group （46 cases） are treated by the above new therapy, the other group （37 eases） are treated by the common way, only one medicine was used. Then an analysis about the treatment results is made. Result The effective rate of the new therapy is 94%, as is obviously higher than the other group＇s rate 87%. PGE1 can strengthen the thrombolytic effect of UK. The comparison between the two group＇s results brings about the apparent difference （P〈0.05）. There was no severe intracranial, or visceral hemorrhaga. Conclusion The new therapy that UK and PEG1 are combined to be injected into the veins can reduce the death rate, the disability rate and the occurrence rate of its complication of the patients suffering from ACI. This new therapy is an effective, safe, thrombolytic method for ACI with fewer side effects.